Clinical trials: Relapsed AML
Leukemia, Myeloid
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia
The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of doses, when combined with cytarabine, in the treatment of patients with primary refractory or relapsed acute myeloid leukemia (AML).
- Trial name
- NCT00512083
- Testing
- AS1411
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 70 people
- Sponsor
- Antisoma Research
Breast Cancer, Leukemia
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00237627
- Testing
- PS-341, Doxil, Velcade
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myeloid Leukemia, Relapsed Adult AML
Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 when given in combination with venetoclax and azacitidine for patients with CD33 positive AML.
- Trial name
- NCT03932318
- Testing
- Lintuzumab-Ac225, Venetoclax, Azacitidine
- Sponsor
- Actinium Pharmaceuticals
Leukemia, Myeloid, Acute
Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."
The goal of this clinical trial is to learn if Revumenib in combination with Fludarabine and Cytarabine can treat children with NUP98-rearranged relapsed or refractory Acute Myeloid Leukemia.
- Trial name
- NCT07686107
- Testing
- Revumenib, Fludarabine, Cytarabine (Ara-C)
- Volunteers
- 24 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Lymphoma
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: Studying samples of blood in the laboratory from patients who have undergone a donor bone marrow transplant may help doctors learn more about changes that occur in DNA and identify biomarkers related to…
- Trial name
- NCT00898612
- Where
- United States
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
This is a phase I/II dose escalation study designed to determine the safety and estimate the efficacy of UD-NK cells combined with FLA chemotherapy in patients age 1-24.99 with relapsed or refractory acute myeloid leukemia.
- Trial name
- KARMA (NCT05503134)
- Testing
- Universal Donor Natural Killer Cells
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nationwide Children's Hospital
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This pilot trial studies decitabine, donor natural killer cells, and aldesleukin in treating patients with acute myeloid leukemia that has come back after previous treatment (relapsed) or has not responded to previous treatment…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT02316964
- Testing
- decitabine, natural killer cell therapy, aldesleukin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sumithira Vasu
Stem Cell Transplant Complications, Graft Vs Host Disease
IS-free Treg HaploHCT
This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory and Ultra-high risk acute myeloid leukemia (AML) and/or…
- Conditions
- Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder)
- Trial name
- NCT04678401
- Testing
- Radiation, Fludarabine, Thiotepa
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Anemia, Chronic Myeloproliferative Disorders
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy, such as busulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anemia, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00301912
- Testing
- filgrastim, busulfan, fludarabine phosphate
- Where
- United States
- Sponsor
- University of California, San Francisco
Chronic Myeloproliferative Disorders, Leukemia
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
RATIONALE: A Web site for stem cell transplant health information and support may be effective in helping parents improve their health-related knowledge, skills, and quality of life, which may also improve their children's…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00782145
- Testing
- educational intervention, informational intervention, internet-based intervention
- Where
- 6 sites in United States
- Volunteers
- 198 people
- Sponsor
- Tufts Medical Center
Acute Myeloid Leukemia
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
This is an international multicenter open label randomized phase III trial in children with relapsed and refractory acute myeloid leukemia (AML) such a disease.
- Trial name
- NCT00186966
- Testing
- Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome), Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan, Hematopoietic stem cell transplant
- Where
- United States
- Volunteers
- 394 people
- Sponsor
- Dutch Childhood Oncology Group
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Phase I trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have residual, recurrent, or metastatic malignant melanoma or other advanced cancer that has not responded to…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003451
- Testing
- recombinant interferon alfa, recombinant interleukin-12
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Acute Myeloblastic Leukemia, Relapsed, Pediatric Acute Lymphoblastic Leukemia, Relapsed
AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia
This study is for patients 2-21 years old who have acute leukemia that has not responded well to chemotherapy and will have a bone marrow transplant. This is a pilot (phase 1) study of AMD3100(also called Plerixafor, Mozobil).
- Trial name
- BMTAMD3100 (NCT01655875)
- Testing
- AMD3100
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Leukemia, Myeloid, Chronic, AML
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.
- Conditions
- Leukemia, Myeloid, Chronic, AML, MDS, Leukemia, Lymphocytic, Acute
- Trial name
- NCT00167167
- Testing
- Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
This phase II trial is studying the side effects and how well giving tetradecanoylphorbol acetate together with dexamethasone and choline magnesium trisalicylate works in treating patients with relapsed or refractory acute…
- Trial name
- NCT01009931
- Testing
- 12-O-tetradecanoylphorbol-13-acetate, Dexamethasone, Choline magnesium trisalicylate
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rutgers, The State University of New Jersey
Relapsed Adult Acute Myeloid Leukemia, Refractory Adult Acute Myeloid Leukemia
Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia
This research study is studying a combination of two targeted therapies as a possible treatment for acute myeloid leukemia (AML) that has relapsed after initial treatment or did not fully respond.
- Trial name
- NCT03125239
- Testing
- Merestinib, LY2874455
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Jacqueline Garcia, MD
Leukemia, Myelocytic, Acute
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
Objectives: 1. Determine the toxicity of infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell transplants. 2.
- Trial name
- NCT00048100
- Testing
- Apheresis, Stem Cell Transplant
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, AML
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
The goal of this clinical trial is to learn about the safety of drug CG009301. It also learns if drug CG009301 works to treat in Participants with relapsed or refractory adult haematological malignancies.
- Conditions
- Leukemia, AML, MDS, AML (Acute Myelogenous Leukemia)
- Trial name
- NCT07347171
- Testing
- CG009301 for Injection
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Cullgen (Shanghai),Inc
Acute Myeloid Leukemia
A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to examine the safety and efficacy of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- NCT01853228
- Testing
- Phase1 and Phase 2: decitabine, Phase 1: cytarabine, Phase 2: cytarabine
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
XK469R in Treating Patients With Refractory Hematologic Cancer
Phase I trial to study the effectiveness of XK469R in treating patients who have refractory hematologic cancer. Drugs used in chemotherapy, such XK469R, work in different ways to stop cancer cells from dividing so they stop…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00095797
- Testing
- R(+)XK469, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.